HOME分野紹介 > がん標的治療トランスレーショナルリサーチ分野

がん標的治療トランスレーショナルリサーチ分野

研究業績

2021年
  1. Nakasuka F, Tabata S, Sakamoto T, Hirayama A, Ebi H, Yamada T, Umetsu K, Ohishi M, Ueno A, Goto H, Sugimoto M, Nishioka Y, Yamada Y, Tomita M, Sasaki AT, Yano S, Soga T. TGF-β-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. Commun Biol. 4:782, 2021. doi: 10.1038/s42003-021-02323-7.
  2. Fairchild CK Jr, Floros KV, Jacob S, Coon CM, Puchalapalli M, Hu B, Harada H, Dozmorov MG, Koblinski JE, Smith SC, Domson G, Leverson JD, Souers AJ, Takebe N, Ebi H, Faber AC, Boikos SA. Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA. Cancers. 13:2310, 2021. doi: 10.3390/cancers13102310.
  3. Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K, Shirasu H, Ebi H, Yamanaka T, Aleshin A, Billings PR, Rabinowitz M, Oki E, Takemasa I, Kato T, Mori M, Yoshino T. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 112:2915-2920, 2021.
  4. Hasegawa H, Taniguchi H, Nakamura Y, Kato T, Fujii S, Ebi H, Shiozawa M, Yuki S, Masuishi T, Kato K, Izawa N, Moriwaki T, Oki E, Kagawa Y, Denda T, Nishina T, Tsuji A, Hara H, Esaki T, Nishida T, Kawakami H, Sakamoto Y, Miki I, Okamoto W, Yamazaki K, Yoshino T. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Sci. 112:314-322, 2021.
  5. Maeda A, Irie K, Hashimoto N, Fukushima S, Ando H, Okada A, Ebi H, Kajita M, Iwata H, Sawaki M. Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. Invest New Drugs. 39:272-277, 2021.
2020年
  1. Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, Ebi H. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 26:5962-5973, 2020.
  2. Costa C, Wang Y, Ly A, Hosono Y, Ellen M, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, Jakubik CT, Henderson LE, Damon LJ, Timonina D, Sanidas I, Pinto CJ, Mino-Kenudson M, Stone JR, Dyson NJ, Ellisen LW, Bardia A, Ebi H, Benes CH, Engelman JA and Juric D. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kalpha inhibitors in breast cancer. Cancer Discov. 2020, 10, 72-85.
  3. Saad MI, McLeod L, Yu L, Ebi H, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ. The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis. Carcinogenesis. 41:527-538, 2020.
  4. Ebi H, Bando H, Taniguchi H, Sunakawa Y, Okugawa Y, Hatanaka Y, Hosoda W, Kumamoto K, Nakatani K, Yamazaki K. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. Cancer Sci. 111:3962-3969, 2020.
2019年
  1. Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z and Ebi H. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. Clin Cancer Res. 25:7089-7097, 2019.
  2. Hosono Y, Masuishi T, Mitani S, Yamaguchi R, Kato S, Yoshino T, Ebi H. Evaluation of ALK fusion newly identified in colon cancer by a comprehensive genomic analysis. JCO Precision Oncology 2019, 3, 1-5.
  3. Ebi H, Bando H. Precision Oncology and the Universal Health Coverage System in Japan. JCO Precision Oncology, 3:1-12,2019.
  4. Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z, Tate MD, Balic JJ, Watkins DN, Cain JE, Bozinovski S, Algar E, Kohmoto T, Ebi H, Ferlin W, Garbers C, Ruwanpura S, Sagi I, Rose-John S and Jenkins BJ. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. EMBO Mol Med. 11:e9976, 2019.
  5. Kondoh C, Horio Y, Hayashi Y, Ebi H, Hida T, Hasegawa Y and Yatabe Y. Anaplastic lymphoma kinase expression in small-cell lung cancer. Histopathology. 75:20-28, 2019.
  6. Saad MI, McLeod L, Yu L, Ebi H, Ruwanpura S, Sagi I, Rose-John S and Jenkins BJ. The ADAM17 Protease Promotes Tobacco Smoke Carcinogen-induced Lung Tumourigenesis. Carcinogenesis. bgz123,2019.
  7. Ebi H, Boikos S, and Faber AC. Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers. Journal of Thoracic Disease. (Suppl 15):S1844-S1846.
2018年
  1. Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene doi: 10.1038/s41388-017-0035-9.
  2. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 29:44-70, 2018.
  3. Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, Bernstein B, Ebi H, Engelman JA, Faber AC.Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM. Clinical Cancer Research 24:197-208, 2018.
  4. Zhang Y, Pitchiaya S, Cieślik M, Niknafs YS, Tien J, Hosono Y, Iyer MK, Yazdani S, Subramanyiam S, Shukla SK, Jiang X, Wang L, Liu TY, Uhl M, Gawronski A, Qiao Y, Xiao L, Dhanasekaran SM, Juckette KM, Kunju LP, Cao X, Patel U, Batish M, Shukla GC, Paulsen MT, Ljungman M, Jiang H, Mehra R, Backofen R, Sahinalp CS, Freier S, Watt A, Guo S, Wei JT, Feng FY, Malik R, Chinnaiyan AM. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat. Genet. In press. 2018
  5. Song KA, Hosono Y, Turner C, Jacob S, Lochmann TL, Murakami Y, Patel NU, Ham J, Hu B, Powell KM, Coon CM, Windle BE, Oya Y, Koblinski JE, Harada H, Leverson JD, Souers AJ, Hata AN, Boikos S, Yatabe Y, Ebi H, Faber AC. Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target. Clin Cancer Res. doi: 10.1158/1078-0432, 2018.
2017年(代表的なもの2本)
  1. Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu SC, Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier SM, Bui HH, Cao X, Malik R, Johnson TM, Beer DG, Feng FY, Zhou W, Chinnaiyan AM. Oncogenic Role of THOR, a Conserved Cancer/Testis Long Noncoding RNA. Cell. 171(7):1559-1572, 2017
  2. Adachi Y, Watanabe K, Kita K, Kitai H, Kotani H, Sato Y, Inase N, Yano S, Ebi H. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. Carcinogenesis 38:1063-1072, 2017.
2016年(代表的なもの2本)
  1. Kitai H, Ebi H*, Tomida S, Floros KV, Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC, Yano S*. Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer. Cancer Discov. 2016 6:754-69, 2016. (*; Co-Corresponding Author)
  2. Kotani H, Ebi H*, Kitai H, Nanjo S, Kita K, Huynh TG, Ooi A, Faber AC, Mino-Kenudson M, Yano S*. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Oncogene 35:3587-97, 2016 (*; Co-Corresponding Author)

(※過去3年間の研究業績を掲載)

このページのトップへ